Sapuri and Klufio indicate that conservative treatment is also possible if the following criteria are met: 1. there are no major congenital malformations; 2. the fetus is alive; 3. there is continuous hospitalization in a well-equipped and well-staffed maternity unit which has immediate blood transfusion facilities; 4. there is careful monitoring of maternal and fetal well-being; and 5. placental implantation is in the lower abdomen away from the liver and spleen. The choice is largely dictated by the clinical situation. Generally, treatment is indicated when the diagnosis is made; however, the situation of the advanced abdominal pregnancy is more complicated. Advanced abdominal pregnancy
Advanced abdominal pregnancy refers to situations where the pregnancy continues past 20 weeks of gestation (versus early abdominal pregnancy < 20 weeks). In those situations, live births have been reported in the lay press where the babies are not uncommonly referred to as Miracle babies. A patient may carry a dead fetus but will not go into labor. Over time, the fetus calcifies and becomes a lithopedion.It is generally recommended to perform a laparotomy when the diagnosis of an abdominal pregnancy is made. However, if the baby is alive and medical support systems are in place, careful watching could be considered to bring the baby to viability. Women with an abdominal pregnancy will not go into labor. Delivery in a case of an advanced abdominal pregnancy will have to be via laparotomy.
However, the valganciclovir patent was rejected by the Indian Patent Office in 2010, although Roche may appeal the rejection. Names
Also known as Cymeval, Valcyt, Valixa, Darilin, Rovalcyte, Patheon, and Syntex. References
External links
"Valganciclovir". Drug Information Portal. U.S. National Library of Medicine.